Nelistotug GSK6097608 represents a intriguing option currently in preclinical trials for treating various autoimmune diseases. This novel entity exhibits a distinct process of suppressing kinase proteins, specifically interacting JAK1, which plays a vital role in inflammatory signaling. Early result